Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. (RYTM)

Joseph Shulman

A named executive officer of RHYTHM PHARMACEUTICALS in every fiscal year CompBrief holds from FY2021 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,410,150

Salary $449,054Stock awards $971,042

FY2022: $950,113

5th of 5 named executive officers at Rhythm Pharmaceuticals by FY2024 total.

5 named officers on file for RHYTHM PHARMACEUTICALS, FY2024

Joseph Shulman’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 8 equity grants, each cited to its filing
  • RYTM’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how RHYTHM PHARMACEUTICALS’s whole pay program stands against its peers

  • RHYTHM PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RYTM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Joseph Shulman’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Joseph Shulman compensation by year

RHYTHM PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as RHYTHM PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2024
Salary$386,250$410,000$449,054
Bonus$0$0—
Stock awards$516,545$72,250$971,042
Option awards$716,625$269,663$1,704,254
Non-equity incentive$157,223$186,000$272,000
Pension and deferred compensation$0$0—
All other$11,600$12,200$13,800
Total$1,788,243$950,113$3,410,150

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RHYTHM PHARMACEUTICALS, INC. DEF 14A filed April 29, 2025, accession 0001558370-25-005818, and prior-year filings. Open the filing on EDGAR.

How this page was built: the RHYTHM PHARMACEUTICALS, INC. filed document, accession 0001558370-25-005818. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

$1.8M
$950K
$3.4M
FY21
FY22
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU29,332$1,642,005—
RSU16,500$923,670—
RSU11,812$661,236—
RSU5,312$297,366—
RSU1,562$87,441—
Option18,844—$27.35
Option40,829—$49.23
Option2,344—$30.66
Option19,922—$6.80

Per the Outstanding Equity Awards at Fiscal Year-End table in RHYTHM PHARMACEUTICALS, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

50 Form 4 lines since the FY2024 proxy (filed April 29, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-18Exercise or conversion10b5-14,188$27.3522,064
2026-11-18Exercise or conversion derivative10b5-19,374$0.0028,126
2026-11-18Sale10b5-145,921$119.9010,461
2026-11-18Exercise or conversion10b5-11,961$6.8017,876
2026-11-18Exercise or conversion derivative10b5-11,961$0.003,984
2026-11-18Exercise or conversion derivative10b5-14,188$0.008,375
2026-11-18Exercise or conversion derivative10b5-124,944$0.0025,306
2026-11-18Exercise or conversion10b5-124,944$49.2347,008

The 8 most recent of 50 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

RHYTHM PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
David MeekerChief Executive Officer$14,663,742
Yann MazabraudExecutive Vice President, Head of International$5,621,623
Hunter SmithChief Financial Officer$5,050,410
Jennifer LeeExecutive Vice President, Head of North America$4,318,212
Joseph Shulman · this pageChief Technical Officer$3,410,150

The full RHYTHM PHARMACEUTICALS compensation record

free company brief

This page is one person within RHYTHM PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the RHYTHM PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RHYTHM PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joseph Shulman's compensation dossier · One-time report. No refunds.